Skip to main content
MNKD
NASDAQ Life Sciences

CEO Michael Castagna Purchases $259,000 in Company Stock

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$2.725
Mkt Cap
$839.574M
52W Low
$2.522
52W High
$6.51
Market data snapshot near publication time

summarizeSummary

MannKind's CEO, Michael Castagna, purchased $259,000 worth of common stock in an open-market transaction, demonstrating executive confidence following recent financial reports.


check_boxKey Events

  • CEO Stock Purchase

    Michael Castagna, CEO and Director, acquired 100,000 shares of common stock for a total of $259,000 at an average price of $2.59 per share on March 10, 2026.

  • Executive Confidence Signal

    This open-market purchase by the top executive indicates strong belief in the company's value and future performance, especially following the recent Q4 and full-year 2025 earnings report on February 26, 2026.


auto_awesomeAnalysis

Michael Castagna, CEO and Director of MannKind Corporation, made a significant open-market purchase of company stock, investing $259,000. This transaction, occurring shortly after the company reported its Q4 and full-year 2025 financial results on February 26, 2026, signals strong confidence from the top executive in the company's future prospects and valuation, despite a reported decline in net income.

At the time of this filing, MNKD was trading at $2.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $839.6M. The 52-week trading range was $2.52 to $6.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MNKD - Latest Insights

MNKD
Mar 10, 2026, 9:30 PM EDT
Filing Type: 4
Importance Score:
7
MNKD
Feb 26, 2026, 8:06 AM EST
Filing Type: 10-K
Importance Score:
8
MNKD
Feb 26, 2026, 8:03 AM EST
Filing Type: 8-K
Importance Score:
7